Storm Therapeutics announced a strategic partnership with Alida Biosciences to analyze transcript‑specific m6A RNA modifications in clinical samples from patients treated with Storm’s METTL3 inhibitor STC‑15. The collaboration will apply Alida’s epitranscriptomic assays (EpiPlex/EpiScout) to validate m6A‑regulated genes and identify biomarkers to guide patient selection and future trial enrichment. STC‑15 is among the first small‑molecule METTL3 inhibitors to reach human trials; Storm is evaluating it in Phase 1b/2 combinations with toripalimab in multiple solid tumors. The deal prioritizes translational RNA‑modification readouts to link epitranscriptomic changes with clinical response. The effort illustrates a growing trend to pair targeted epitranscriptomic therapies with specialized assays to deconvolute mechanism and enable biomarker‑driven development.